This is a routine early-stage clinical update with no data readout until H2 2027. No immediate catalyst for the stock. Monitor for DSMB safety reviews and any interim updates, but the next material event is topline data release.
PCVX drugs
PCVX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 3 $46.93entry
- T+1 · 6mo ago +3.90%α +3.49% · $48.76
- T+5 · 5mo ago −3.22%α +0.60% · $45.42
- T+20 · 5mo ago +24.42%α +25.42% · $58.39
- T+60 · 3mo ago +30.31%α +27.81% · $61.16
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Vaxcyte dosed the first participant in a Phase 1 first-in-human study of VAX-A1, a prophylactic vaccine candidate for Group A Streptococcus. This is an early-stage clinical milestone with no efficacy data yet; topline results are not expected until H2 2027.
Key Facts
- First participant dosed in Phase 1 study of VAX-A1 for Group A Strep.
- Study is randomized, double-blind, placebo-controlled, dose-escalation, two-stage, enrolling ~80 healthy adults aged 18-40.
- Primary objective: safety and tolerability; secondary: antigen-specific immune responses.
- Topline data expected in second half of 2027.
- Group A Strep causes ~800M new cases and >600,000 deaths annually worldwide; no approved vaccine exists.
- VAX-A1 targets four conserved antigens (ScpA, SLO, SpyAD, modified GACPR) using Vaxcyte's cell-free protein synthesis platform.
Financial Impact
No financial data disclosed; early-stage clinical milestone with no revenue impact.
Risk Factors
- Clinical failure or safety issues in Phase 1 could halt the program.
- Long timeline to data (H2 2027) means no near-term catalyst.
- Group A Strep vaccine development has historically been challenging with prior failures.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3305592 |
Track record
29 reports on PCVX
5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +10.87% at T+5 after the Oct 8, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $62.40 Now $63.37 +1.55% settles Dec 15
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $64.69 Now $63.37 −2.04% settles Dec 11
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $63.89 Now $63.37 −0.81% settles Dec 7
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $63.89 Now $63.37 −0.81% settles Dec 7
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $61.92 Now $63.37 +2.34% settles Dec 4
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $61.92 Now $63.37 +2.34% settles Dec 4
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $60.81 Now $63.37 +4.21% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $60.81 Now $63.37 +4.21% settles Dec 2
- Oct 9, 20265w ago 8-K Bearish 6/10 Entry $70.65 to $67.53 Now $63.37 +10.30% ▲ +4.42% +1.15% vs SPY
- Oct 8, 20265w ago 424B5 Bearish 6/10 Entry $71.38 to $63.89 Now $63.37 +11.22% ▲ +10.49% +4.93% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers